Alan List, MD

Founder

Alan List, MD is a hematologist, medical oncologist and physician scientist who is internationally recognized for his many contributions in the development of effective treatment strategies for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). He is the former President and CEO of Moffitt Cancer Center, past President of the Society of Hematologic Oncology and has authored more than 450 peer-reviewed manuscripts, chapters and books. His work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the U.S. Food and Drug Administration and approval for the treatment of MDS patients with chromosome 5q deletion. Dr. List was also a key leader in the development and FDA approval of two other agents for MDS, i.e., azacitidine (Vidaza®) and most recently, luspatercept (Reblozyl®). His laboratory investigations identified a previously unrecognized form of programmed cell death termed pyroptosis driving the pathobiology of MDS.

Dr. List is a Charter Fellow in the National Academy of Inventors, an inductee into the Florida Inventors Hall of Fame, and holds 18 U.S. patents with more than 50 applications filed. He is the recipient of the Celgene 2016 Career Achievement Award for Clinical Research in Hematology, the General Motors Cancer Research Foundation Merit Award, the J.P. McCarthy Foundation International Prize, the Emil J. Freireich Award, a Joshua Lederberg Society fellow and the Aplastic Anemia & MDS International Foundation Leadership in Science Award. He has served as a clin/dev or scientific advisor for numerous major pharmaceutical and biotechnology companies and has served on the board of directors of the Laboratory for Advanced Medicine (LAM) and TuHura BioSciences Inc., as well as non-profit entities such as the MDS Foundation, the International MDS Foundation, the Society for Hematologic Oncology (SOHO), and others.